Business Daily Media

The Times Real Estate

.

HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council

Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions

HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today that a collaborative research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions" ("Project") led by Prof.

Zhiwei Chen of The University of Hong Kong ("HKU") on our therapeutic HIV vaccine ("ICVAX") has been awarded HK$66.7 million of funding under the Theme-based Research Scheme ("TRS") of the Research Grants Council ("RGC") for a second 5-year term.

HIV/AIDS are a global health concern, especially significant in Hong Kong. Based on Centre for Health Protection's record, a cumulative total of 12,143 cases of HIV infection and 2,507 cases of AIDS are found in Hong Kong, which have been steadily increasing over the years. The current combination antiretroviral therapy ("cART") target suppressing viral reproduction while this project will further investigate the effect of using our PD-1-enhanced DNA vaccine technologies on immunogenicity.

The Project is led by Professor Zhiwei Chen, Director of the AIDS Institute and Chair Professor of the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of HKU, and the Principal Scientific Advisor of Immuno Cure. The research will be performed in collaboration with Immuno Cure, Chinese University of Hong Kong Phase 1 Clinical Trial Centre, The Third People's Hospital of Shenzhen, and other hospitals in the Mainland where the collaborative team of researchers will investigate and determine the mechanism of PD-1-based DNA vaccine-mediated 7-year cART-free virologic control in SHIV-infected rhesus monkeys; the impact of PD-1-base DNA vaccine on cART-treated people living with HIV-1 ("PLWH"); and the sustained cART-free HIV-1 control using analytical treatment interruption ("ATI") and combinational immunotherapy.

Immuno Cure will contribute to the manufacturing of ICVAX and the design and management of the clinical trials with our aim to determine the ATI amongst the PLWH of ICVAX Phase 1 Trial; to optimise the immunogenicity of ICVAX by conducting a multi-centre Phase 2 Trial; and to determine the immunotherapeutic efficacy by combining ICVAX with other complementary strategies. This Project will strengthen Hong Kong Research Consortium on HIV/AIDS in collaboration with international experts and scientific advisors, and also reveal mechanisms underlying a promising "Made in Hong Kong" immunotherapy in clinical trials. It will ultimately contribute to the understanding of long-term viral control and potential alternative treatment strategies for HIV-1 without cART treatment in future.

Prof. Zhiwei CHEN, Director of AIDS Institute of HKU and the Principal Scientific Advisor of Immuno Cure, said "Preliminary Phase 1 Trial data demonstrated that the HKU patented PD-1-enhanced DNA vaccine ICVAX has shown convincing safety and immunogenicity profiles in PLWH. Our team members are very grateful that this TRS grant will allow us to expand our translational research to benefit more and more PLWH."

Dr. Xia JIN, CEO of Immuno Cure & Co-PI of the Project, said, "We are excited to be a key member of the collaborative research team led by Prof. Chen, with whom we have many years of close working relationship. This TRS-funded research will enhance our understanding of the mechanisms of the immune protection and enable us to further investigate the potential of ICVAX towards functional cure of HIV/AIDS."

Dr. Percy CHENG, Chairman of Immuno Cure, concluded, "Immuno Cure is delighted to have earned RGC's support and recognition of our ICVAX research which is of strategic importance to Hong Kong's long-term development. This milestone allows us to carry out academic collaborative research with HKU's AIDS Institute and other top ranked universities in Hong Kong and the Mainland for the advancement of our combat against HIV/AIDS. We are also grateful for the involvement of all the global expert advisors organised by Prof. Chen."

Hashtag: #ImmunoCure #HKU #AIDS

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher learning in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled "Potentiating Host Immunity for HIV-1 Functional Cure", the institute is currently leading the second 5-year term research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions".

To learn more about HKU and AIDS Institute of HKU, please visit and

About Research Grant Council and Theme-based Research Scheme

To learn more about RGC, please visit:

To learn more about TRS, please visit:

News from Asia

PAObank Shared in World Internet Conference Asia-Pacific Summit in Hong Kong

Insights on the Potential of Commercial Data: A Path to Enhanced Financing Efficiency and Financial Inclusion HONG KONG SAR - Media OutReach Newswire - 15 April 2025 - ​The World Internet Conferen...

Consumer goods expo highlights China's growing allure for global brands

HAIKOU, CHINA - Media OutReach Newswire - 15 April 2025 - ​The fifth China International Consumer Products Expo (CICPE), held on the tropical island province of Hainan, has reaffirmed the country...

Recognising Purpose-Driven Excellence: ACES Awards 2025 Opens Nominations for the Philippines’ Most Visionary Leaders and Companies

MANILA, PHILIPPINES - Media OutReach Newswire - 16 April 2025 - In a region rich with ambition, the Philippines continues to lead with sustainability and purposeful leadership. The Asia Corporate ...

Hey! Chips Launches Singapore’s First Clean-Label Fruit Bites Snack

SINGAPORE - Media OutReach Newswire - 16 April 2025 - Singapore’s leading clean snack brand, Hey! Chips, is proud to introduce its latest innovation: Hey! Fruit Bites. A first-of-its-kind freeze-...

Sustainability progress to 2030 delivering value for Hongkong Land

Key achievements include: 33.3% reduction in Scope 1 and 2 carbon emissions against 2019 baseline, making good progress toward 2030 target...

Crayon’s Biennial Future of Operations Study Uncovers What is Driving SMB IT Spend in APAC

SYDNEY, AUSTRALIA - Media OutReach Newswire - 16 April 2025 - ​Crayon, a global leader in IT services and innovation, today announced the latest release of its biennial Future of Operations study ...

Shama Hub Metro South Hong Kong Unveils Characteristic Panda-Themed Rooms This Spring

HONG KONG SAR - Media OutReach Newswire - 16 April 2025 - Shama Hub Metro South Hong Kong ("Shama Hub Metro South"), a contemporary urban retreat and distinguished member of the ONYX Hospitality...

Zero Fintech Group Limited (Stock Code: 0093.HK) Announces Record-Breaking 2024 Annual Results

HONG KONG SAR - Media OutReach Newswire - 16 April 2025 - Zero Fintech Group Limited ("Zero Fintech" or the "Company", stock code: 0093.HK), a leading fintech innovator, is proud to announce its s...

All roles, all levels, all markets: General Assembly launches first-of-its-kind one-stop AI Academy to help companies close their AI skills gap

This is the first in Singapore to offer flexible AI courses geared towards all organisational roles – from business and operational teams to decision-makers – all in one place Unl...

Leong Yik Launches New Website & Enhanced Client Experience to Mark 7 Years in SG

SINGAPORE - Media OutReach Newswire - 16 April 2025 - Leong Yik Engineering & Contractor has launched a newly redesigned website to mark its 7th year of operations in Singapore. The new platfo...

Cutting edge AI technology designed for doctors to reduce patient wait times launched in NZ

New Zealand specialist doctors now have access to Artificial Intelligence technology to help reduce patient wait times and experts say it could be...

Launchd Takes Off: Former AFL Stars Lead Tech-Powered Platform Set to Disrupt Talent and Influencer Marketing

Backed by Institutional Capital, Launchd Combines Five Leading Agencies and Smart Technology to Deliver Measurable Results Influencer marketing i...

Meet the Australian fintech unlocking rewards for small businesses

Small businesses make up 98 per cent of all businesses in Australia, yet they continue to bear the brunt of economic uncertainty. According to Credi...

Teleperformance (TP) Business Insights Report Reveals Key Shifts in Consumer Behaviour

TP’s Business Insights report  into consumer behaviors and preferences, taking in more than 57,000 respondents across 19 sectors, is shedding new li...

HubSpot launches platform-wide AI tools to help businesses close the adoption gap

HubSpot today unveiled more than 200 updates across its customer platform to help businesses grow better. The release introduces smarter tools, new AI...

Why Every Leader Needs a Personal Branding Strategy in 2025

One of the best investments you can make in 2025? Your Personal Brand.In today’s competitive and digitally driven business world, authenticity and...

Sell by LayBy